AKBA

Akebia Therapeutics, Inc.

1.45

USD

AKBA Earnings Reports

Positive Surprise Ratio

AKBA beat 18 of 40 last estimates.

45%

Next Report

Date of Next Report

Mar 11, 2026

Estimate for Q4 25 (Revenue/ EPS)

$57.30M

$0.00

Implied change from Q3 25 (Revenue/ EPS)

-2.49%

Implied change from Q4 24 (Revenue/ EPS)

+23.24%

-100.00%

Akebia Therapeutics, Inc. earnings per share and revenue

On Nov 10, 2025, AKBA reported earnings of 0.00 USD per share (EPS) for Q3 25, beating the estimate of -0.01 USD, resulting in a 100.00% surprise. Revenue reached 58.77 million, compared to an expected 59.40 million, with a -1.07% difference. The market reacted with a -18.14% price change (close before vs. close after earnings).

Looking ahead to Q4 25, 7 analysts forecast an EPS of 0.00 USD, with revenue projected to reach 57.30 million USD, implying an increase of 0.00% EPS, and decrease of -2.49% in Revenue from the last quarter.

FAQ

What were Akebia Therapeutics, Inc.'s earnings and revenue for the latest quarter Q3 2025?

For Q3 2025, Akebia Therapeutics, Inc. reported EPS of $0.00, beating estimates by 100%, and revenue of $58.77M, -1.07% below expectations.

How did the market react to Akebia Therapeutics, Inc.'s Q3 2025 earnings?

The stock price moved down -18.14%, changed from $2.04 before the earnings release to $1.67 the day after.

When is Akebia Therapeutics, Inc. expected to report next?

The next earning report is scheduled for Mar 11, 2026.

What are the forecasts for Akebia Therapeutics, Inc.'s next earnings report?

Based on 7 analysts, Akebia Therapeutics, Inc. is expected to report EPS of -- and revenue of $57.30M for Q4 2025.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.